Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D COWEN

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 18, 2003
[Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials]V Beckendorf, J M Bachaud, P Bey, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin BPaul D Greenspan, Kirk L Clark, Scott D Cowen, et al.
Journal of Medicinal Chemistry|December 23, 2016
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 InhibitorsScott D Cowen, Daniel Russell, Leslie A Dakin, et al.
Journal of Medicinal Chemistry|December 14, 2001
Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug designP D Greenspan, K L Clark, R A Tommasi, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 16, 2008
[Ductal carcinoma in situ: role of the boost]D Azria, H Auvray, I Barillot, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|February 18, 2003
[Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials]V Beckendorf, J M Bachaud, P Bey, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin BPaul D Greenspan, Kirk L Clark, Scott D Cowen, et al.
Journal of Medicinal Chemistry|December 23, 2016
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 InhibitorsScott D Cowen, Daniel Russell, Leslie A Dakin, et al.
Journal of Medicinal Chemistry|December 14, 2001
Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug designP D Greenspan, K L Clark, R A Tommasi, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 16, 2008
[Ductal carcinoma in situ: role of the boost]D Azria, H Auvray, I Barillot, et al.
Pageof 9